VCAM-1

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search


Vascular cell adhesion molecule 1
Image:PBB Protein VCAM1 image.jpg
PDB rendering based on 1ij9.
Available structures: 1ij9, 1vca, 1vsc
Identifiers
Symbol(s) VCAM1; CD106; DKFZp779G2333; INCAM-100; MGC99561
External IDs OMIM: 192225 MGI98926 Homologene838
RNA expression pattern

Image:PBB GE VCAM1 203868 s at tn.png

More reference expression data

Orthologs
Human Mouse
Entrez 7412 22329
Ensembl ENSG00000162692 ENSMUSG00000027962
Uniprot P19320 Q3TR98
Refseq NM_001078 (mRNA)
NP_001069 (protein)
NM_011693 (mRNA)
NP_035823 (protein)
Location Chr 1: 100.96 - 100.98 Mb Chr 3: 116.1 - 116.12 Mb
Pubmed search [1] [2]

Vascular cell adhesion molecule 1, also known as VCAM1, is a human gene.


This gene is a member of the Ig superfamily and encodes a cell surface sialoglycoprotein expressed by cytokine-activated endothelium. This type I membrane protein mediates leukocyte-endothelial cell adhesion and signal transduction, and may play a role in the development of artherosclerosis and rheumatoid arthritis. Two alternatively spliced transcripts encoding different isoforms have been described for this gene.[1]


VCAM-1 (vascular cell adhesion molecule-1), also known as CD106, is a molecule with a considerable role in the human immune system.

Structure

VCAM-1 contains six or seven immunoglobulin domains, and is expressed on both large and small vessels only after the endothelial cells are stimulated by cytokines.

Function

VCAM-1 promotes the adhesion of lymphocytes, monocytes, eosinophils, and basophils. Interestingly, certain melanoma cells can use VCAM-1 to adhere to the endothelium, and VCAM-1 may participate in monocyte recruitment to atherosclerotic sites. As a result, VCAM-1 is a potential drug target.

Upregulation of VCAM-1 in endothelial cells by cytokines occurs as a result of increased gene transcription (e.g., in response to Tumor necrosis factor-alpha (TNF-α) and Interleukin-1, aka IL-1) and through stabilization of Messenger RNA (mNRA) (e.g., Interleukin-4, aka IL-4). The promoter region of the VCAM-1 gene contains functional tandem NF-kB (nuclear factor-kappa B) sites.

The sustained expression of VCAM-1 lasts over 24 hours. Primarily, VCAM-1 is an endothelial ligand for VLA-4 (Very Late Antigen-1 or α4β1) of the β1 subfamily of integrins, and for integrin α4β7. VCAM-1 expression has also been observed in other cell types (e.g., smooth muscle cells).

References

Further reading

External links


WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch

Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

related articles